Trinity Biotech PLC TRIB.OQ reported a quarterly adjusted loss of 46 cents per share for the quarter ended September 30. The lone analyst forecast for the quarter was for a loss of 54 cents per share.
Revenue rose 3.2% to $15.15 million from a year ago; analysts expected $16.50 million.
Trinity Biotech PLC's reported EPS for the quarter was a loss of 46 cents.
Trinity Biotech PLC shares had risen by 34.5% this quarter and lost 31.0% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 1.8% in the last three months.
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
This summary was machine generated from LSEG data November 15 at 02:31 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
Sep. 30 2024 | -0.54 | -0.46 | Beat |
Jun. 30 2024 | -0.65 | -0.71 | Missed |
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。